Abstract: A single-piece ceramic dental implant is provided, with a distal enossal threaded region, a gingival intermediate region and a proximal region. A thread is arranged in the threaded region and has a core radius and an outer radius of the thread. A proximally accessible insertion geometry for screwing the threaded region into a bone tissue is arranged in the intermediate region, wherein the insertion geometry is designed as a non-rotationally-symmetrical outer structure. The proximal region includes at least one structure for fastening a single-part or multi-part attachment element. An implant diameter in every section perpendicular to the implant axis, in the intermediate region is equal to or larger than the double of the core radius of the thread. Thus each implant diameter through the insertion geometry is equal to or larger than the double of the core radius of the thread.

Abstract: An object of the present invention is to provide hexagonal plate-shaped zinc oxide particles which can be used as a cosmetic raw material, a heat releasing filler and the like, a method for production of the same, and a cosmetic, a heat releasing filler, a heat releasing resin composition, a heat releasing grease and a heat releasing coating composition each comprising the same. Provided are hexagonal plate-shaped zinc oxide particles having hexagonal-shaped surfaces, wherein the primary particle diameter is 0.01 ?m or more and the aspect ratio is 2.5 or more, and 50% or more of 250 particles in a transmission electron microscope photograph satisfy both the requirements (1) the particle has a hexagonal-shaped surface; and (2) Dmin/Dmax?0.

Abstract: A gel, comprising: an ester and a polymer having at least one of the following rigid block groups; polystyrene, polyethylene, polyvinyl chloride, and phenolics as well as one elastic block that is a member of the group consisting of ethylene/butadiene copolymers, polyisoprene, polybutadiene, ethylene/propylene copolymers, or ethylene-propylene/diene copolymers, wherein the polymer is either triblock copolymers, star polymers, radial polymers, multi-block copolymers, or combinations thereof, wherein the composition is substantially free of mineral oils; wherein the ester's chemical formula is: Wherein n=1, 2, 3, and 4, and R1 represents a member of the group consisting of: hydrogen, hydrocarbyl, phenyl, methoxyphenyl, alkylphenyl, substituted alkyl, and substituted phenyl; R2 represents a member of the group consisting of: hydrogen, hydrocarbyl, phenyl, methoxyphenyl, alkylphenyl, substituted alkyl, substituted phenyl, alkylene, phenylene, substituted alkylene, and substituted phenylene, and R3 represents

Abstract: Agent for obtaining a stable aqueous composition comprising a polymer constituted of: at least one A monomer of acrylic acid and/or methacrylic acid and/or any of their salts, at least one B monomer of alkyl acrylate and/or methacrylate, and at least one C monomer corresponding to the following formula (I): T-[(EO)n(PO)n?(BO)n?]-Z ??(I) ?in which: T represents one end enabling the co-polymerization of the C monomer, [(EO)n(PO)n?(BO)n?] represents a polyalkoxylated chain constituted of alkoxylated units, distributed into blocks, alternatively or statistically, chosen from among EO ethoxylated units, PO propoxylated units and BO butoxylated units, representing, independently from each other, 0 or a whole number between 1 and 150, the sum of n, -n? and n? not being null, and Z represents a fatty chain, linear or branched, of at least 16 carbon atoms, at least one crosslinked monomer D.

Abstract: Provided is an emulsion composition comprising the following ingredients (A), (B), (C), (D), (E), and (F): (A) glyceryl monofatty acid ester derived from a linear-chain fatty acid having 10 to 24 carbon atoms; (B) a higher alcohol having 10 to 24 carbon atoms; (C) a ceramide; (D) an anionic surfactant; (E) a polar oil selected from branched fatty acid esters having an IOB of from 0.2 to 0.85 and having a hydroxyl group or an amino group; and (F) water, wherein the mass ratio of the total content of ingredients (A), (B), and (C) and ingredient (D) in terms of acid to the content of ingredient (E), ((A)+(B)+(C)+(D))/(E), is from 1.2 to 25.

Abstract: The invention relates to aqueous compositions comprising an anionic surfactant and a hyperbranched polyesteramide having at least one quaternized amine endgroup. The compositions, in particular in the form of shampoo preparations are suited for increasing the volume of hair treated therewith. Furthermore, such compositions provide styling attributes and increase the wet-combability of hair.

Abstract: The invention relates to a composition that can be subcutaneously or intradermally injected, comprising: a filling agent; and a fibroblast growth medium.

Abstract: Method for coloring hair wherein a non-diluted hair coloring composition is applied to the hair, e.g. the hair roots and a diluted hair coloring composition is applied to the hair, e.g. the hair lengths and tips, wherein a dilutant composition comprising water and/or a non-aqueous liquid is added to the non-diluted hair coloring composition to obtain the diluted hair coloring composition.

Abstract: A high internal water phase water-in-oil emulsified cosmetic in which, in a system formed of an oil phase including silicone elastomer, polydimethylsiloxane and polyether modified silicone and a water phase including water in an amount of 60% or greater by mass. The water phase, at least, including one nonionic surfactant having an HLB value of 14 or greater, selected from a group consisting of polyoxyalkylene alkyl ethers, polyglycerin fatty acid esters, polyoxyalkylene glycerin fatty acid esters and polyalkyleneglycol fatty acid esters, in an amount of 0.03 to 0.6% by mass, is blended with pigments including an organic pigment, in an amount of 0.05 to 8% by mass. The viscosity at the shear rate of 3.83 sec?1 at 25° C. is 1 to 100 Pa·sec, as well as an applicator with an applying part having a surface roughness Ra of 3 to 300 ?m to store the cosmetic.

Abstract: The present invention provides for an oral serum made from natural ingredients that advantageously reduces oral bacteria. Further, toothpaste and oral rinse compositions are provided. A method for reducing oral bacteria using the oral serum of the present invention is additionally described herein.

Abstract: The invention provides a method for inhibiting dopa oxidase activity, for inhibiting melanin production, or for whitening skin using haguro-so or an organic solvent extract thereof, or a compound of formula (I):

Abstract: The present invention relates to natural anti-bacterial toothpaste composition containing improvement in tooth pain, antibacterial mouth and nerve stability and particularly, it enables to contribute to improvement in tooth pain, antibacterial mouth and nerve stability, which represent effects of Na2SiO3-10H2O and oriental medicine, due to more than 63˜75% of SiO3, and Na2SiO3-10H2O and oriental medicine containing natural minerals like calcium, iron, magnesium, etc.

Abstract: The present invention provides an inhalation-type pharmaceutical composition for arthritis and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising indomethacin, flurbiprofen, celecoxib, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can remove harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid can indirectly reduce the side effects on the user.

Abstract: The present invention generally relates to compositions and methods for treatment of subjects having or at risk of arteriosclerosis, hypertension, sickle-cell anemia, or other conditions. In some cases, the composition may include nitric oxide, peptides, or both. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

Abstract: A method for the treatment and/or prevention of hyperandrogenism and/or polycystic ovary syndrome and/or related disorders comprising the vaginal administration of at least one insulin-sensitizing agent.

Abstract: The present invention relates to active substances in particulate form, to methods for preparing them and to their uses. The present invention provides particulate powders, such as might be of use for delivery using a dry powder inhaler (DPI) or similar delivery device, having properties which may be beneficial to the DPI delivery process.

Abstract: The invention relates to a self-emulsifiable liquid composition intended to be diluted in an aqueous intermediate solution and then incorporated into the drinking water of livestock animals, and also to the use of such a composition. The invention is characterized in that the composition comprises at least—between 1% and 12% by weight of the florfenicol active ingredient, relative to the total volume of the composition; —at least 50% by weight, relative to the total volume of the composition (p/v), of a mixture of C8-C10 saturated polyglycosylated glycerides having an HLB (hydrophilic-lipophilic balance) of less than 16; and—at least 5% by weight, relative to the total volume of the composition (p/v), of a surfactant.

Abstract: This disclosure provides a range of amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.

Abstract: The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles may comprise prophylactic, therapeutic and/or diagnostic agents.

Abstract: Novel compositions, formulations and dosage forms comprising stabilized micronized opioid particles are disclosed. Exemplary opioids include oxycodone, oxymorphone, hydrocodone, and hydromorphone, including as free bases or as salts. Stabilized micronized opioid particles having a Dv90 particle size distribution of less and or equal to 10? or less than or equal to 20? are disclosed. Methods for micronizing an opioid to provide stabilized micronized opioid particles are also disclosed.

Abstract: The present invention relates to a fast dissolving granulate formulation containing the veterinary drug azaperone and a method for preparing said granulate formulation.

Abstract: Nucleic acids are prepared by dissolving compounds containing them in a suitable solvent or solvent system and forming microspheres from the resulting solution. The microspheres are administered to an individual as protection from conditions where delivery of nucleic acids is useful, such as in treatment of autoimmune disease.

Abstract: Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.

Abstract: Conventional spray-drying methods are improved by incorporation of a pressure nozzle and a diffuser plate to improve the flow of drying gas and a drying chamber extension to increase drying time, such improvements leading to the formation of homogeneous solid dispersions of drugs in concentration-enhancing polymers.

Abstract: The subject invention provides R(+)-N-methyl-propargyl-aminoindan or a pharmaceutically acceptable salt thereof and a composition containing R(+)-N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof, and a compound of R(+)-N-methyl-propargyl-aminoindan or a salt thereof.

Abstract: A pharmaceutical composition comprising a solid unit dosage form comprising: (i) ritonavir or a pharmaceutically acceptable salt and ester thereof; (ii) darunavir or a pharmaceutically acceptable salt and ester thereof.

Abstract: Provided are oral dosage forms that contain carbinoxamine in an immediate release format, and pseudoephedrine in a prolonged release format. The biphasic oral dosage forms may also contain other active ingredients in combination with carbinoxamine, including other decongestants, antitussives, analgesics and expectorants.

Abstract: A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin or its HCl salt, which is subject to intra-molecular cyclization, which formulation includes a tablet core containing one or more fillers, and other conventional excipients, which tablet core includes a coating thereon which may include two or more layers, at least one layer of which is an inner seal coat layer which is formed of one or more coating polymers, a second layer of which is formed of medicament which is the DPP4-inhibitor and one or more coating polymers, and an optional, but preferable third outer protective layer which is formed of one or more coating polymers. A method for forming the coated tablet is also provided.

Abstract: A method for producing starch films comprises the following steps: preparing a mixture comprising starch and water, wherein more than 50 weight percent of the starch is present in the form of particles of granular starch; shaping the mixture to form a film in a shaping process; solidifying the mixture by increasing the temperature of the mixture during and/or after the shaping process by more than 5° C. Films produced by this method have starch particles bonded to one another. A device for performing this method comprises a shaping device for enabling shaping of the starch material to form a film, and has a heating device for performing a heat treatment for destructuring of the starch during and/or after the shaping.

Abstract: A method for producing starch soft capsules comprises the following steps: preparing a mixture comprising starch, plasticizer and water, wherein more than 50 weight percent of the starch is present in the form of particles of granular starch; shaping the mixture to form a film in a shaping process; solidifying the mixture by increasing the temperature of the mixture during and/or after the shaping process by more than 5° C.; and shaping the film to form a soft capsule. Soft capsules produced by this method have starch particles bonded to one another. A device for performing this method comprises a shaping device to enable shaping of the starch material to form a film, and a heating device to perform a heat treatment to destructure the starch during and/or after the shaping. It comprises a rotary die device.

Abstract: The present invention relates to spatially arranging a plurality of particles in a device for the oral delivery of a pharmaceutical. In particular, the plurality of particles is utilized for the oral delivery of a pharmaceutical to a subject via the drinking device.

Abstract: Meshes for use to control the movement of bodily fluids, such as blood, are described herein. The mesh can be partially or completely biodegradable or non-biodegradable. In one embodiment, the mesh is formed from one or more self-assembling peptides. The peptides can be in the form of fibers, such as nanofibers. The peptides can be assembled prior to formation of the mesh or after the mesh has been formed but before it is applied. Alternatively, the mesh can be prepared from unassembled peptides, which assemble at the time of application. The peptides can assemble upon contact with bodily fluids (e.g., blood) or can be contacted with an ionic solution to initiate assembly.

Abstract: The present invention relates to an antimicrobial composition and a method for disinfection involving the antimicrobial composition. It particularly relates to an antimicrobial composition for personal cleaning, oral care or hard surface cleaning applications. It was found that compositions comprising thymol, selected propen-2-yl-methyl-cyclohexanols, and a carrier provide synergistic antimicrobial action. In a preferred aspect the composition also comprises 1 to 80%-wt of one or more surfactants.

Abstract: A pharmaceutical composition in the form of a tablet including a first portion and a second portion, wherein said first portion includes guaifenesin having an immediate release profile and a second drug having a sustained release profile, and wherein the second portion includes guaifenesin having a sustained release profile. The second drug can be in the form of a drug-resin complex. The second drug can be either an anti-tussive or a decongestant. The drug-resin complex includes a drug complexed to an ion exchange resin. The ion exchange resin can be a polystyrene sulfonate resin, polacrilex resin, polacrilin potassium, cholestyramine resin, or a colestyramine resin. The drug-resin complex can be provided with a coating, the coating thickness being selected to obtain the desired release profile. The drug-resin complex can be provided with a coating level of from 5% to 50%. The coating level can be from 10% to 35%.

Abstract: This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogs, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role.

Abstract: Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes.

Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.

Abstract: The invention provides methods and compositions for treating dysregulated blood glucose disorders.

Abstract: The present invention aims to provide an amino acid-containing granule preparation improved in the ease of taking medication than conventional products, which disintegrates rapidly. The amino acid-containing granule preparation of the present invention containing granules having a maximum particle size of substantially not more than 1000 ?m and a bulk density of not less than 0.57 g/mL markedly improves ease of taking medication without impairing disintegration property, as compared to conventional amino acid-containing granule preparations.

Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of fibromyalgia, restless leg syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of motor neurone disease, diabetic neuropathy, postherpetic neuralgia, acute opioid withdrawal management, obsessive-compulsive disorder, premature ejaculation, PTSD, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, bipolar depression, depression, stress, cancer pain and lower back pain.

Abstract: The present invention provides for a method to increase the triplet yield of a photosensitizer by the coupling to metal surface plasmons which leads to increased singlet oxygen generation by electric field enhancement or enhanced energy absorption of the photosensitizer. The extent of singlet oxygen enhancement can be tuned for applications in singlet oxygen based clinical therapy by modifying plasmon coupling parameters, such as metallic nanoparticle size and shape, photosensitizer/metallic nanoparticle distance, and the excitation wavelength of the coupling photosensitizer.

Abstract: Heterocyclic compounds which modulate cannabinoid receptors are presented. Pharmaceutical compositions containing these compounds, methods of using these compounds as modulators of cannabinoid receptors and processes for synthesizing these compounds are also described herein.

Abstract: There is provided a dry powder pharmaceutical composition for inhalation useful for preventing and/or treating influenza virus infections contains as a medicinal component a compound represented by formula (I): and optionally a compound represented by formula (II): a pharmacologically acceptable salt thereof, or a hydrate thereof.

Abstract: Cervical cancer is one of the most common malignancies and is associated with a dismal prognosis. The most common therapeutic option for cervical cancer consists of surgery in early stages, and chemotherapy or radiotherapy in more advanced stages of the disease. Although treatment options have increased for some patients, overall progress has been modest. This invention relates to a method for treating cancer comprising administering an anti-cancer compound. More particularly, the present invention relates to an anti-cervical-cancer compound for treating human cervical cancer and tumor.

Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 10 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam.

Abstract: Embodiments of the invention generally relate to methods and supplements for increasing sex steroids and human growth hormone in a human being.

Abstract: Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of acute exacerbations of chronic obstructive pulmonary disease. Treatment may involve a single dose of the active ingredient by oral administration.

Abstract: Embodiments herein provide formulations and methods for treatment of inflammatory skin diseases using allantoin in an amount from about 0.5% to about 15.0% by weight. Inflammatory skin diseases treated by embodiments herein include, without limitation, cutaneous porphyria, sclerodema, epidermolysis bulosa, psoriasis, decubitus ulcers, pressure ulcers, diabetic ulcers, venous stasis ulcers, sickle cell ulcers, ulcers caused by burns, eczema, urticaria, atopic dermatitis, dermatitis herpetiform, contact dermatitis, arthritis, gout, lupus erythematosus, acne, alopecia, carcinomas, psoriasis, rosacea, miliaria, skin infections, post-operative care of incisions, post-operative skin care following any variety of plastic surgery operations, skin care following radiation treatment, care of dry, cracked or aged skin and skin lines as well as other conditions affecting the skin and having an inflammatory component, symptoms thereof, or a combination thereof.

Abstract: Azaindoles having inhibitory activity on RSV replication and having the formula I compositions containing these compounds as active ingredient and processes for preparing these compounds and compositions.

Abstract: Methods of increasing tonic inhibition in a subject in need thereof, for example a subject with Fragile X syndrome or Angelman syndrome are disclosed. Methods of treating secondary insomnia in a subject with a neurodegenerative disease or disorder are also disclosed.